Health Robotics reported 16 new contracts in 3Q2012 including 8 I.V. Robots (3 for Oncology and 5 for non-hazardous IVs) and 8 i.v.SOFT agreements, continuing its 3-year supremacy of the global Sterile Compounding Automation market.
On a year-to-date basis, YTD 2012 contracts reached an all-time record of 79 new installations over the last 9-month period, a 46% increase over 2011's 54 new sales on a year-to-date basis. Health Robotics continues to benefit from its decision to transition into a higher-margin direct-sales approach, now accounting for 75%+ of Health Robotics' revenues, compared to prior years' dependency on distributors.
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "I'm very pleased with 3Q2012 results, especially following our record 1Q and 2Q sales and also following Health Robotics' winning 100% of all worldwide I.V. Robot's publicly announced purchases in 2010 and 2011. Hospital pharmacists continue to recognize the undeniable fact that Health Robotics' Second Generation modular architecture of networked medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than its global competitors;, and delivering payback periods/R.O.I. of less than one year."
During 3Q2012, Health Robotics and/or some of its partners (Rivosem and Grifols) signed 16 new installations under contract at: Duke University Medical Center, Wyoming Medical Center (Casper), AZ Damiaan (Belgium) Hospital Doctor Negrin (Canary Islands), Mangiagalli's Neonatology Institute (Milan), La Maddalena Oncology Institute (Palermo, Italy), Campo di Marte Hospital (Lucca, Italy), Trakya University Hospital (Turkey) and Umraniye Egitim Arastirma Hospital (Istanbul).
Mr. DeViedma concluded: "Despite the effects of the global economic crisis in the USA and Western Europe, Health Robotics continues its multi-year market momentum, further demonstrating its resiliency and ability to excel and expand, even in this difficult financial environment. This is a testament of Health Robotics' proven advantages over its competitors, and its customers' published return on investment studies. With the upcoming publication this Fall of two peer-reviewed scientific validation studies for Health Robotics' Oncology robots in American and European university hospitals, I further expect that the contrast between our proven Oncology technology and that of our competitors' will continue to be self-evident."
Competitors: Loccioni-AEA, IHS-RIVA, MDS (now Fresenius Kabi), FHT/Baxa (now Baxter)